GlassScriptPhysician profile
Edward William Schaefer
NPI 1275507444
$13,258.14
in general payments reported to CMS, 2019-2025
42 companies · $1,605 in 2025
The $1,605 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,005 · 2020: $1,419 · 2021: $1,867 · 2022: $1,836 · 2023: $1,647 · 2024: $1,879 · 2025: $1,605.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,067 · Education: $63.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,066.89 |
| Education | $63.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,462.91 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,499.45 | 2019-2025 | Fasenra, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,119.48 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Regeneron Healthcare Solutions, INC. | $987.50 | 2019-2025 | Dupixent |
| Jazz Pharmaceuticals INC. | $801.65 | 2019-2025 | |
| Genzyme Corporation | $738.96 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $662.87 | 2020-2025 | Acthar |
| Mylan Specialty L.P. | $630.31 | 2019-2024 | Yupelri |
| Insmed, INC. | $609.71 | 2019-2025 | Arikayce |
| Harmony Biosciences LLC | $605.43 | 2020-2025 | Wakix |
| Takeda Pharmaceuticals U.S.A., INC. | $389.34 | 2020-2025 | Glassia, Cuvitru |
| Genentech USA, INC. | $273.35 | 2019-2025 | Xolair |
| Grifols USA, LLC | $245.96 | 2022-2025 | Prolastin-C Liquid |
| Amgen INC. | $244.03 | 2021-2025 | Tezspire |
| Mallinckrodt Enterprises LLC | $226.13 | 2019 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Schaefer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.